Checkpoint Therapeutics (NASDAQ:CKPT) Receives Buy Rating from D. Boral Capital

Checkpoint Therapeutics (NASDAQ:CKPT)‘s stock had its “buy” rating reissued by equities research analysts at D. Boral Capital in a report issued on Monday,Benzinga reports. They currently have a $4.80 price objective on the stock. D. Boral Capital’s price target suggests a potential upside of 18.81% from the stock’s previous close.

CKPT has been the topic of several other reports. HC Wainwright reaffirmed a “neutral” rating and set a $4.10 price objective on shares of Checkpoint Therapeutics in a report on Tuesday, March 11th. Lake Street Capital reissued a “hold” rating and set a $4.10 target price (down previously from $7.00) on shares of Checkpoint Therapeutics in a report on Monday, March 10th.

Checkpoint Therapeutics Stock Performance

Shares of Checkpoint Therapeutics stock opened at $4.04 on Monday. The firm has a 50-day simple moving average of $3.32 and a two-hundred day simple moving average of $3.27. Checkpoint Therapeutics has a fifty-two week low of $1.38 and a fifty-two week high of $4.50. The company has a market cap of $197.29 million, a P/E ratio of -2.20 and a beta of 1.41.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its quarterly earnings results on Friday, March 28th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.47). Equities research analysts forecast that Checkpoint Therapeutics will post -0.94 EPS for the current year.

Insiders Place Their Bets

In other news, CFO William Garrett Gray sold 74,110 shares of the firm’s stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $3.67, for a total transaction of $271,983.70. Following the completion of the sale, the chief financial officer now owns 1,458,644 shares in the company, valued at $5,353,223.48. This trade represents a 4.84 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO James F. Oliviero III sold 10,331 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $3.15, for a total value of $32,542.65. Following the completion of the transaction, the chief executive officer now owns 3,775,019 shares in the company, valued at $11,891,309.85. This represents a 0.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 93,674 shares of company stock valued at $336,011. Insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Checkpoint Therapeutics

Large investors have recently modified their holdings of the business. Walleye Capital LLC purchased a new stake in Checkpoint Therapeutics in the 3rd quarter valued at about $148,000. State Street Corp raised its stake in shares of Checkpoint Therapeutics by 32.2% in the 3rd quarter. State Street Corp now owns 94,424 shares of the company’s stock valued at $212,000 after acquiring an additional 23,000 shares during the period. Geode Capital Management LLC raised its stake in shares of Checkpoint Therapeutics by 41.2% in the 3rd quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock valued at $958,000 after acquiring an additional 124,787 shares during the period. Virtu Financial LLC acquired a new position in shares of Checkpoint Therapeutics in the 3rd quarter worth approximately $30,000. Finally, PVG Asset Management Corp boosted its position in shares of Checkpoint Therapeutics by 9.2% during the 3rd quarter. PVG Asset Management Corp now owns 149,870 shares of the company’s stock worth $336,000 after purchasing an additional 12,676 shares during the period. Institutional investors and hedge funds own 22.00% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.